

Resource Summary Report

Generated by [dkNET](#) on Aug 8, 2026

Charles River Laboratories

RRID:SCR_003792

Type: Tool

Proper Citation

Charles River Laboratories (RRID:SCR_003792)

Resource Information

URL: <http://www.criver.com/>

Proper Citation: Charles River Laboratories (RRID:SCR_003792)

Description: Commercial organism provider selling mice, rats and other model animals. American corporation specializing in a variety of pre-clinical and clinical laboratory services for the pharmaceutical, medical device and biotechnology industries. It also supplies assorted biomedical products and research and development outsourcing services for use in the pharmaceutical industry. (Wikipedia)

Abbreviations: CRL

Synonyms: Charles River Laboratories Inc., Charles River, Charles River Laboratories International Inc.

Resource Type: biomaterial supply resource, material resource, organism supplier

Keywords: RIN, Resource Information Network, pre-clinical, clinical, pharmaceutical, medical device, biotechnology, drug, drug discovery, RRID Community Authority

Resource Name: Charles River Laboratories

Resource ID: SCR_003792

Alternate IDs: SCR_013551, grid.452317.6, nlx_158088, nif-0000-00462, Wikidata: Q28974283

Alternate URLs: <https://ror.org/01tasya06>

License: Resource specific license

License URLs: <https://www.criver.com/about-us/terms-conditions>

Record Creation Time: 20220129T080221+0000

Ratings and Alerts

No rating or validation information has been found for Charles River Laboratories.

No alerts have been found for Charles River Laboratories.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 11510 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Pero SC, et al. (2026) Novel antibody cocktail therapy targeting extracellular tumor-specific mutations to treat EMT6 cell line-derived triple-negative breast cancer. Scientific reports, 16(1).

Sumii M, et al. (2026) Plasminogen Activator Inhibitor-1 Mediates Tolerance to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer. Molecular cancer therapeutics, 25(3), 435.

Lee HS, et al. (2026) Zinc-Mediated Lysosomal Destabilization Links Mitochondrial Damage to Neuronal Death in a Cellular MPP+ Model of Parkinson's Disease. Journal of neurochemistry, 170(2), e70363.

Vaquié AM, et al. (2026) Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism. Molecular oncology, 20(2), 307.

Baurès M, et al. (2026) Targeting pre-existing club-like cells in prostate cancer potentiates androgen deprivation therapy. EMBO molecular medicine, 18(3), 943.

Palaniappan S, et al. (2026) Unraveling Endocannabinoid Signaling Pathways in Cisplatin-Induced Ototoxicity. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 40(4), e71568.

Mariancini A, et al. (2026) IL1R2 Deficiency Unleashes Neutrophil-Mediated Antitumor Potential in Sarcoma. Cancer immunology research, 14(5), 751.

Bai G, et al. (2026) LARS promotes osteosarcoma proliferation through leucine-dependent PRIM2 translation and DNA replication activation. Journal of experimental & clinical cancer research : CR, 45(1).

Pinto-Pardo N, et al. (2026) The contribution of dorsal horn cyclin-dependent kinase 5 (CDK5) to the initiation and maintenance of chronic pain is defined by the nature of injury. British journal of pharmacology.

Bontekoe E, et al. (2026) FOXM1-Specific TCR-Engineered T Cells Target Non-Small Cell Lung Cancer. *Cancer immunology research*, 14(6), 958.

Amorim R, et al. (2026) Mitochondria-targeted antioxidant AntiOxBEN2 prevents metabolic dysfunction-associated steatotic liver disease (MASLD) by enhancing fatty acid oxidation and mitochondrial bioenergetics. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*, 196, 119022.

Darlington DN, et al. (2026) Trauma and Hemorrhage Lead to An Elevation in Fecal Short-Chain Fatty Acids. *Shock (Augusta, Ga.)*, 65(5), 847.

Gupta PK, et al. (2026) MRS and Optical Imaging Studies of Therapeutic Response to Combination Therapy Targeting BRAF/MEK in Murine Melanomas. *Academic radiology*, 33(5), 1793.

Drouillard D, et al. (2025) Biosafety assessment of engineered CCL20 locked dimers in vivo. *Cell biology and toxicology*, 42(1), 14.

Kaplan HS, et al. (2025) Sensory input, sex and function shape hypothalamic cell type development. *Nature*.

Sanches ES, et al. (2025) Methylphenidate triggers retinal oxidative stress and mitochondrial dysfunction under physiological conditions but has beneficial effects in inflammatory settings. *Neuropharmacology*, 279, 110623.

Kovacheva L, et al. (2025) Recovery of the full in vivo firing range in post-lesion surviving DA SN neurons associated with Kv4.3-mediated pacemaker plasticity. *eLife*, 14.

Shmuel S, et al. (2025) Imaging and targeting S1PR1 in HER2+ tumors. *Nuclear medicine and biology*, 148-149, 109057.

Cluzet V, et al. (2025) Pharmacologic Inhibition of SIRT1 Limits the Growth of Tumoral and Metastatic Granulosa Cells by Affecting mTOR, Myc, and E2F Pathways. *Molecular cancer therapeutics*, 24(8), 1197.

Olaitan G, et al. (2025) Focused Ultrasound Modulates Dopamine in a Mesolimbic Reward Circuit. *Journal of neurochemistry*, 169(2), e70001.